Company profile
Can-Fite BioPharma Ltd.
AMEX:CANFBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PICLIDENOSON | phase3 | — | 12 | completed, terminated, withdrawn |
| NAMODENOSON | phase2 | — | 4 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (22)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00790218 | phase1_2 | completed | 2009-02-01 | 2012-12-01 | Can-Fite BioPharma | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma |
| NCT00790673 | phase1_2 | completed | 2009-07-01 | 2011-06-01 | Can-Fite BioPharma | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 |
| NCT06643260 | phase3 | not_yet_recruiting | 2025-06-01 | 2027-12-01 | Can-Fite BioPharma | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy |
| NCT00837291 | phase2 | withdrawn | 2018-11-01 | 2018-12-01 | Can-Fite BioPharma | A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee |
| NCT02927314 | phase2 | completed | 2017-11-27 | 2020-03-01 | Can-Fite BioPharma | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease |
FDA applications (0)
No records yet.